Bicara Therapeutics (BCAX) vs Precigen (PGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Precigen (PGEN) has outperformed Bicara Therapeutics (BCAX) over the past year, gaining 136.0% versus a loss of 4.1%. Precigen is the larger company by market cap ($2.72 billion vs $1.14 billion), about 2.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCAX | PGEN |
|---|---|---|
| Share price | $17.26 | $7.60 |
| Market cap | $1.14B | $2.72B |
| 1-day change | +5.12% | +0.80% |
| YTD return | +2.55% | +81.82% |
| 1-year return | -4.11% | +136.02% |
| 5-year return | — | +63.44% |
| EPS (TTM) | $-3.08 | $-1.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $9.68M |
| Revenue growth (YoY) | — | +146.73% |
| Net income (latest FY) | — | $-250.64M |
| Operating margin | — | -1141.13% |
| Net margin | — | -2588.21% |
| 52-week high | $30.99 | $8.98 |
| 52-week low | $13.70 | $2.99 |
| Distance from 52-week high | -44.30% | -15.37% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +105.68% | +79.61% |
| Average volume | 623.17K | 5.03M |
| Shares outstanding | 66.17M | 358.04M |
| Employees | 103 | 160 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Precigen is about 2.4 times larger than Bicara Therapeutics by market value ($2.72B vs $1.14B).
- PGEN has outperformed BCAX by 140.1 percentage points over the past year.
About Bicara Therapeutics
BCAX stock →Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors.
Healthcare · Biotechnology · 103 employees
About Precigen
PGEN stock →Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.
Healthcare · Biotechnology · 160 employees
BCAX vs PGEN FAQ
Which is bigger, Bicara Therapeutics or Precigen?
Precigen (PGEN) is larger, with a market capitalization of $2.72B compared with $1.14B for Bicara Therapeutics (BCAX).
Which stock has performed better over the past year, BCAX or PGEN?
PGEN returned +136.02% over the past 12 months, compared with -4.11% for BCAX (price return, excluding dividends). Past performance does not predict future results.
Are Bicara Therapeutics and Precigen in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.